Remission Rates Following Antidepressant Therapy With Bupropion or Selective Serotonin Reuptake Inhibitors: A Meta-Analysis of Original Data From 7 Randomized Controlled Trials
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
BACKGROUND: Although it is widely believed that the various classes of antidepressants are equally effective, clinically meaningful differences may be obscured in individual studies because of a lack of statistical power. The present report describes a meta-analysis of original data from a complete set of studies comparing the norepinephrine/dopamine reuptake inhibitor (NDRI) bupropion with selective serotonin reuptake inhibitors (SSRIs; sertraline, fluoxetine, or paroxetine). METHOD: Individual patient data were pooled from a complete set of 7 randomized, double-blind studies comparing bupropion (N = 732) with SSRIs (fluoxetine, N = 339; sertraline, N = 343; paroxetine, N = 49) in outpatients with major depressive disorder (DSM-III-R or DSM-IV); 4 studies included placebo (N = 512). Response and remission rates were compared at week 8 or endpoint in both the intent-to-treat sample, using the last-observation-carried-forward (LOCF) method to account for attrition, and the observed cases. Tolerability data, including incidence of sexual side effects, were also compared. RESULTS: The LOCF response and remission rates for the bupropion (62% and 47%) and SSRI (63% and 47%) groups were similar; both active therapies were superior to placebo (51% and 36%; all comparisons, p < .001). The same pattern of results was demonstrated on the observed cases analyses. Although bupropion and SSRIs were generally well tolerated, SSRI therapy resulted in significantly higher rates of sexual side effects as compared to both bupropion and placebo. SSRIs were also associated with more somnolence and diarrhea, and bupropion was associated with more dry mouth. CONCLUSION: Bupropion and the SSRIs were equivalently effective and, overall, both treatments were well tolerated. The principal difference between these treatments was that sexual dysfunction commonly complicated SSRI therapy, whereas treatment with bupropion caused no more sexual dysfunction than placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, SSRIs and other traditional antidepressants are problematic as they typically take weeks before therapeutic effects are observed and require daily administration”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Thase et al., 2005
In the citing paper
“Particularly relevant in the present context are previous reports [290,296,297] that although both DA and non-DA agents can be used to effectively treat mood disorders, DA agents generally have superior effects on symptoms of anhedonia, specifically when compared with non-DA agents [19,298-300].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [290]
In the citing paper
“Bupropion, a DA and norepinephrine reuptake inhibitor, is an effective antidepressant [290] that seems to specifically increase feelings of positive affect [291].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [290]
Citations
Cites
Still being checked.
Cited by
Items 201–300 of 310
Tabah, A., Gold, L. S., Marcum, Z. A., & Hansen, R. N. (2023) · Pharmacoepidemiology · doi:10.3390/pharma2030018 · Cited by 8
Personality traits and escitalopram treatment outcome in major depression
Aluoja, A., Tõru, I., Raag, M., Eller, T., Võhma, Ü., & Maron, E. (2018) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2018.1465590 · Cited by 8
Improving depression outcome: new concepts, strategies and technologies
Alpert, J. E. (2006) · Journal of Psychopharmacology · doi:10.1177/1359786806064304 · Cited by 8
Navigating Pleiotropy in Precision medicine: Pharmacogenes from Trauma to Behavioral Health
Oberg, V., Differding, J. A., Fisher, M., Hines, L. J., & Wilke, R. A. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.6 · Cited by 7
NEFA can serve as good biological markers for the diagnosis of depression in adolescents
Liu, G., Li, Z., Lin, S., Luo, Z.-Y., Yin, Y., Zhou, Y., & Ning, Y. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.274 · Cited by 7
Tonozzi, T. R., Braunstein, G. D., Kammesheidt, A., Curran, C., Golshan, S., & Kelsoe, J. R. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0088 · Cited by 7
Gómez, C., Carrasco, C., & Redolat, R. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.10.008 · Cited by 7
Zuilhof, Z., Norris, S., Blondeau, C., Tessier, P., & Blier, P. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s175203 · Cited by 9
Demitrack, M. A. (2007) · Psychopharm Review · doi:10.1097/01.idt.0000271143.75925.33 · Cited by 8
Bee, R., Ahmad, M., & Verma, S. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220516105907 · Cited by 7
Bossarte, R. M., Ross, E. L., Liu, H., Turner, B., Bryant, C., Zainal, N. H., Puac‐Polanco, V., Ziobrowski, H. N., Cui, R., Cipriani, A., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.082 · Cited by 6
Rethorst, C. D., Trombello, J. M., Chen, P. M., Carmody, T. J., Lazalde, A., & Trivedi, M. H. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101103 · Cited by 6
Association between smoking and minimal-mild depressive symptomatology in heavy smokers
Moreno-Coutiño, A. B., Ruiz‐Velasco, S., & Icaza, M. E. M. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 7
Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation
Camacho, M. B., & Anastasio, T. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00925 · Cited by 7
Moreno-Coutiño, A. B., Facultad de Psicología, U. N. A. D. M., García-Anguiano, F., Ruiz‐Velasco, S., Medina‐Mora, M. E., de México., I. D. I. E. M. A. Y. E. S. U. N. A., & México., D. G. D. I. N. D. P. R. D. L. F. M. (2015) · Salud Mental · doi:10.17711/sm.0185-3325.2015.058 · Cited by 6
Bushnell, G., Horton, D. B., Olfson, M., Samples, H., Suarez, E. A., & Calello, D. P. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0111 · Cited by 6
Unipolare Depression – Pharmakotherapie und Psychotherapie (ICD-10 F3)
Schmauß, M., Schramm, E., & Berger, T. (2009) · Elsevier eBooks · doi:10.1016/b978-3-437-24900-6.50011-3 · Cited by 5
Johnson, B. (2009) · Medical psychiatry · doi:10.3109/9781420084887.013 · Cited by 5
An Evidence-Based Approach to the Management of Depression
Maurer, D., & Colt, R. (2006) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2006.09.003 · Cited by 6
Curtiss, F. R., & Fairman, K. A. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.5.468 · Cited by 5
The management of depression: An international naturalistic survey
Lecrubier, Y., Bahk, W., Matos, J. D., & Briley, M. (2008) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500802108948 · Cited by 6
Managing Depression in Clinical Practice
Friedman, E. S., & Anderson, I. M. (2010) · Springer eBooks · doi:10.1007/978-1-84996-465-4 · Cited by 5
Pharmacologic Strategies for Treatment-resistant Depression: An Update on the State of the Evidence
Thase, M. E. (2005) · Psychiatric Annals · doi:10.3928/00485713-20051201-04 · Cited by 5
Self-citationThe Failure of Evidence-Based Medicine to Guide Treatment of Antidepressant Nonresponders
Thase, M. E. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1202 · Cited by 4
Self-citationJohnson, B. (2009) · doi:10.3109/9781420084887-15 · Cited by 4
Pharmacological Treatment of Major Depressive Disorder: A Review
Papakostas, G. I., Bech, P., & Fava, M. (2009) · Wiley eBooks · doi:10.1002/9780470745892.ch2 · Cited by 5
Ayyash, S., Davis, A. D., Alders, G. L., MacQUEEN, G. M., Strother, S. C., Hassel, S., Zamyadi, M., Arnott, S. R., Harris, J. K., Lam, R. W. M., et al. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.12.011 · Cited by 5
Demitrack, M. A. (2010) · Psychopharm Review · doi:10.1097/01.idt.0000369508.83887.db · Cited by 4
Closing the antidepressant efficacy gap between clinical trials and real patient populations
Wade, A. G. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600934982 · Cited by 6
Ethnopsychopharmacology: Clinical and scientific writing pearls
Leung, J. G. (2023) · Mental Health Clinician · doi:10.9740/mhc.2023.12.276 · Cited by 3
Oluboka, O. J., Habert, J., Khullar, A., Robinson, D. J., Katzman, M. A., Klassen, L. J., Soares, C., Chokka, P. R., Oakander, M. A., McIntyre, R. S., et al. (2025) · CNS Spectrums · doi:10.1017/s1092852925000276 · Cited by 3
The Controversy Over Antidepressant Drugs in an Era of Evidence-Based Practice
Littrell, J. L., & Lacasse, J. R. (2012) · Social Work in Mental Health · doi:10.1080/15332985.2012.699444 · Cited by 4
Rethorst, C. D., Trombello, J. M., Chen, P. M., Carmody, T. J., Goodman, L. C., Lazalde, A., & Trivedi, M. H. (2024) · BMC Psychology · doi:10.1186/s40359-024-02053-5 · Cited by 4
Kaya, D., Savitskaya, U., & Bloom, N. (2025) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000396 · Cited by 4
Calegare, B. F. A., Costa, A., Fernandes, L., Dias, A. L., Torterolo, P., & Almeida, V. (2016) · Sleep Science · doi:10.1016/j.slsci.2016.05.010 · Cited by 3
Antidepressant medications: a comprehensive review of efficacy, safety, and future directions
Shah, N., Parmar, J., Shandilya, S., Parmar, D., & Singhal, P. K. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20253726 · Cited by 2
Fava, M., & Papakostas, G. I. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50045-7 · Cited by 2
Recent advances in the biological treatment of mood disorders
McDonald, G., & Hallahan, B. P. (2009) · Irish Journal of Psychological Medicine · doi:10.1017/s0790966700000331 · Cited by 2
Bupropion versus other antidepressive agents for depression
Furukawa, T. A., Ogawa, Y., Takeshima, N., Hayasaka, Y., Chen, P., Cipriani, A., & Barbui, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011036 · Cited by 3
RetractedCurrent Advances in the Treatment of Major Depression: Shift Towards Receptor Specific Drugs
Kumar, A. (2013) · InTech eBooks · doi:10.5772/52298 · Cited by 2
Barros, B. R., Schacht, A., Happich, M., Televantou, F., Berggren, L., Walker, D. J., & Dueñas, H. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01661 · Cited by 2
Brand, L., van Zyl, J., Minnaar, E. L., Viljoen, F. P., du Preez, J. L., Wegener, G., & Harvey, B. H. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00622.x · Cited by 4
Intérêts de la kétamine : de l’effet antidépresseur à l’effet anti-suicide ?
Laforgue, E., Sauvaget, A., Bulteau, S., & Vanelle, J. (2016) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2015.12.007 · Cited by 2
Cognitive Behavioral Therapy for Adherence and Depression in Diabetes
Gonzalez, J. S., Kane, N. S., & Chang, T. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-29294-6_6 · Cited by 2
Sposato, L. A., & Fustinoni, O. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4088-7.00107-3 · Cited by 2
Holsboer‐Trachsler, E., & Holsboer, F. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_53 · Cited by 2
Poissant, H., & Rapin, L. (2012) · Europe PMC (PubMed Central) · Cited by 2
Demitrack, M. A. (2010) · Psychopharm Review · doi:10.1097/01.idt.0000384050.93852.3e · Cited by 2
Besckow, E. M., Pires, C. S., Giehl, M. R., Godoi, B., Bortolatto, C. F., & Brüning, C. A. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148714 · Cited by 2
Mindfulness-based Yoga intervention for women with elevated levels of depressive symptoms
Schuver, K. J. (2014) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 3
Acute rTMS Treatment for Depression
Fitzgerald, P. B., & Daskalakis, Z. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-91519-3_4 · Cited by 1
Recovery-Oriented Treatments in Major Depressive Disorder
Sampogna, G., Vincenzo, M. D., Giallonardo, V., Luciano, M., & Fiorillo, A. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_14 · Cited by 1
Chapter 20. Psychopharmacology
Mulsant, B. H., & Pollock, B. G. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375196.ds20 · Cited by 1
Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland
Kelly, J. R., Sheridan, C., Iusan, P., Coakley, L., Burke, L., Brennan, C., MacDonald, A. A., Ivers, J., Trépel, D., Tormey, G., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag028 · Cited by 1
Sialorrhea possibly associated with bupropion: a case report and review of potential mechanisms
Du, H., Bai, M., Yang, L., Jia, S., Yang, Y., Wang, W., Luo, X., & Wei, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1979464 · Cited by 1
Disfunción sexual asociada a antidepresivos
Urbina, S. P. V., & Diep, R. S. (2012) · Psiquis - Hospital Psiquiátrico Fray Bernardino Alvarez · Cited by 1
Antidepressant Pharmacotherapy – Do the Benefits Outweigh the Risks?
Getz, A. M., Xu, F., & Sye, N. (2012) · InTech eBooks · doi:10.5772/31962 · Cited by 1
The Association between Depression, Anxiety and Clinical Outcomes for Type 2 Diabetes Mellitus
Heidari, E. (2018) · Cited by 1
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · Medical psychiatry · doi:10.3109/9781420084887.002 · Cited by 1
Self-citationRobinson, J. D., Karam‐Hage, M., Kypriotakis, G., Beneventi, D., Blalock, J. A., Cui, Y., González, R. O., Tayar, J. H., Chaftari, P. S., & Cinciripini, P. M. (2022) · American Journal on Addictions · doi:10.1111/ajad.13282 · Cited by 1
Itamura, R. (2022) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2022-0034 · Cited by 1
Fluvoxamina no transtorno depressivo maior: um estudo multicêntrico aberto
Porto, J. A. D., Mello, A. F., Kerr-Corrêa, F., dos Santos, A., Moreno, R. A., dos Santos, C. H. R., Chaves, A. V., Versiani, M., Nardi, A. E., de Oliveira, I. R., et al. (2007) · Jornal Brasileiro de Psiquiatria · doi:10.1590/s0047-20852007000100006 · Cited by 1
Badaracco, M. A. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050829 · Cited by 1
Pharmacogenomics of Antidepressant Medications
Ehret, M. J. (2006) · Journal of Pharmacy Practice · doi:10.1177/0897190007300729 · Cited by 1
Awadalla, S. (2021) · Nottingham ePrints (University of Nottingham) · Cited by 2
Bupropion w leczeniu depresji - skuteczność, objawy uboczne i bezpieczeństwo leku
Urban‐Kowalczyk, M. (2008) · Psychiatria i Psychologia Kliniczna
Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder
Maneeton, N. (2012) · InTech eBooks · doi:10.5772/30340
Unipolare Depression–Pharmakitherapie und Psychotherapie (ICD-10 F3)
Schmauß, M., Schramm, E., & Berger, T. (2008) · Elsevier eBooks · doi:10.1016/b978-343724780-4.50011-7
Children in Foster Care and Excessive Medications
Littrell, J. L. (2012) · Digital Archive @ GSU
Acute rTMS Treatment for Depression
Fitzgerald, P. B., & Daskalakis, Z. J. (2013) · Springer eBooks · doi:10.1007/978-3-642-36467-9_4
Bupropion in the treatment of major depressive disorder: a comparison with paroxetine
Calandra, C., Terranova, F., Loiacono, P., Caudullo, V., Russo, R., Luca, M., & Cafiso, M. (2010) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology
Ehret, M. J., & Chavez, B. (2006) · Journal of Pharmacy Practice · doi:10.1177/0897190007300736
Björkholm, C. (2013) · Figshare
CYP2C19 polymorphisms in drug metabolism and response
Chang, M. (2014) · Figshare
Gedge, L. (2010) · QSpace (Queen's University Library)
Tolerability and profile of the side effects of bupropion
Gálvez, V., Cardoner, N., Crespo-Blanco, J. M., Navarro-Odriozola, V., García–Parés, G., Sánchez-Pérez, M., Roncero, C., & Eucb, G. (2011) · Actas Españolas de Psiquiatría
Psychobiological Processes and Therapies in Depression
Cristancho, P., & Thase, M. E. (2015) · Wiley eBooks · doi:10.1002/9781119114482.ch4
Self-citationGlutamate Approaches Towards the Treatment of Mood Disorders
Jones, C. K., Conn, P. J., & Lindsley, C. W. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00258
Outcomes in the Treatment of Major Depressive Disorder
Thase, M. E., & Koenig, A. M. (2009) · doi:10.3109/9781420084887-4
Self-citationIskandarani, E. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-3466 · Cited by 1
Masters, A. R. (2016) · IUScholarWorks (Indiana University) · doi:10.7912/c2/318
Ketamine: The Glutamatergic Antidepressant and Its Efficacy
Tracy, D. K., Caddy, C., & Shergill, S. S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_41
Antidepressant Therapy for Depression: An Update
Gupta, D., & Mahesh, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_17
Camacho, M. B. (2018) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Gourgouvelis, J. (2017) · e-scholar@UOIT (University of Ontario Institute of Technology)
Pharmacological Interventions in Older Adults
Patel, J. J., Smith, D. W., Heafner, J., Christopher, N. G., & Grossberg, G. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-10814-4_9
Examining a Hypothyroid Model of Depressive Symptoms in Mice: Tests of Behavioral Measures
Ovadia, H. (2019) · Cited by 1
Hamati, R. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24287
Jansen, T. L. (2020) · Journal of International Crisis and Risk Communication Research · Cited by 1
Joel Paris, M. D. (2010) · Wiley eBooks · doi:10.1002/9780470666630.refs
Holsboer‐Trachsler, E., & Holsboer, F. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_28 · Cited by 1
Current Treatments for Depression
Krystal, J. H., & Charney, D. S. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0031
Friedman, E. S. (2009) · doi:10.1007/978-1-907673-24-5_6
Friedman, E. S., & Anderson, I. M. (2014) · doi:10.1007/978-1-907673-79-5_6 · Cited by 1
Friedman, E. S. (2010) · Springer eBooks · doi:10.1007/978-1-84996-465-4_6
Metadata
- Authors
- Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y.
- Affiliations
- University of Pittsburgh Medical Center (US)
- GlaxoSmithKline (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-08-15
- Volume
- 66
- Issue
- 08
- Pages
- 974-981
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2089694151
- Cited by
- 304
- References
- 0
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 13 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 10 · 2017: 15 · 2016: 18 · 2015: 10 · 2014: 20 · 2013: 18 · 2012: 23
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30915)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- bupropion, selective serotonin reuptake inhibitors, major depressive disorder, antidepressant efficacy, remission rate, sexual dysfunction, drug tolerability, fluoxetine, sertraline, paroxetine, norepinephrine-dopamine reuptake inhibitors, placebo comparison
- MeSH terms
- Major Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Bupropion, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.